Nkarta Inc
$ 2.51
8.66%
24 Feb - close price
- Market Cap 178,284,000 USD
- Current Price $ 2.51
- High / Low $ 2.66 / 2.30
- Stock P/E N/A
- Book Value 4.76
- EPS -1.38
- Next Earning Report 2026-03-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.15 %
- ROE -0.27 %
- 52 Week High 2.74
- 52 Week Low 1.31
About
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.
Analyst Target Price
$14.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-12 | 2025-05-07 | 2025-03-19 | 2024-11-07 | 2024-08-13 | 2024-05-09 | 2024-03-21 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-16 |
| Reported EPS | -0.29 | -0.31 | -0.43 | -0.35 | -0.39 | -0.34 | -0.58 | -0.57 | -0.52 | -0.6 | -0.63 | -0.67 |
| Estimated EPS | -0.338 | -0.35 | -0.45 | -0.4 | -0.36 | -0.45 | -0.56 | -0.59 | -0.67 | -0.68 | -0.7 | -0.64 |
| Surprise | 0.048 | 0.04 | 0.02 | 0.05 | -0.03 | 0.11 | -0.02 | 0.02 | 0.15 | 0.08 | 0.07 | -0.03 |
| Surprise Percentage | 14.2012% | 11.4286% | 4.4444% | 12.5% | -8.3333% | 24.4444% | -3.5714% | 3.3898% | 22.3881% | 11.7647% | 10% | -4.6875% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-25 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.32 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NKTX
2026-02-15 07:27:18
Nkarta, Inc. (NASDAQ:NKTX) has an average "Moderate Buy" rating from six analysts, with an average 12-month price target of $13.25 significantly above its current trading price of $1.97. The company is a clinical-stage biotechnology firm focused on off-the-shelf natural killer cell therapies for cancer. Recent insider selling by the CEO and institutional trading activity are noted, with institutions owning a significant portion of the stock.
2026-01-23 10:28:22
Nkarta, Inc. (NASDAQ:NKTX) recently saw significant insider selling, with a large transaction by Paul Hastings at US$2.06 per share, below the current stock price of US$2.40. Over the past year, insiders have not purchased any shares, and recent selling activity totaled US$66k. This behavior, alongside minimal insider ownership (approximately US$770k), suggests caution for potential investors, despite the stock's recent 22% increase.
2026-01-21 19:57:48
Nkarta (NKTX) President Nadir Mahmood sold 5,649 shares of common stock for $11,693 to cover tax obligations related to Restricted Stock Units vesting. Following this, Mahmood directly owns 167,727 shares. The company is also advancing clinical programs for its NK cell therapy, NKX019, with Stifel adjusting its price target to $11 while maintaining a Buy rating.
2026-01-21 19:27:48
Nkarta CEO Paul J. Hastings sold 26,046 shares of NKTX stock worth $53,915 to cover tax obligations related to Restricted Stock Units vesting. Despite the sale, Hastings still directly owns 390,023 shares, and analysts maintain a bullish outlook on the company. Nkarta, a clinical-stage biotech company, recently announced positive clinical data for its NKX019 therapy and had its price target adjusted by Stifel from $12 to $11, while retaining a Buy rating due to accelerated trial enrollment.
2026-01-21 18:28:43
Nkarta, Inc. (NASDAQ:NKTX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $13.25. Insider selling by CEO Paul J. Hastings was reported, but institutional investors have shown mixed activity. The company is a clinical-stage biotech focusing on NK cell therapies for cancer.
2026-01-20 23:58:04
Nkarta (NASDAQ:NKTX) CEO Paul Hastings sold 26,046 shares of the company's stock on January 15th at an average price of $2.07, totaling $53,915.22. This sale reduced his stake by 6.26%, leaving him with 390,023 shares valued at approximately $807,347.61. The biopharmaceutical company's shares are trading around $2.04, and analysts maintain a "Moderate Buy" rating with an average target price of $13.25.
